Stomach cancer

Your skin is a mirror of your health – here’s what yours might be saying

Retrieved on: 
Tuesday, January 30, 2024

It is the largest and most visible organ in the human body.

Key Points: 
  • It is the largest and most visible organ in the human body.
  • Being the most visible of our organs, the skin also offers us a view into the body tissues that it protects.
  • So don’t think of your skin merely aesthetically – think of it as a reflection of your health.

Bullseye

  • But while the vast majority of tick bites won’t make you ill, there is one rash that should prompt a visit to your doctor if you spot it.
  • Erythema migrans, a rash named for its ability to rapidly expand across the skin, is a hallmark of Lyme disease, a potentially severe bacterial illness.
  • This rash forms a classic target pattern, like a bullseye on a dartboard.

Purpura

  • Some rashes are given a colourful namesake – purpura is one such example.
  • Purpura refers to a rash of small purple or red dots.
  • Purpura signals an issue with either the walls of the tiny blood vessels that feed the skin or the blood within them.

Skin spiders


Skin rashes can also take on recognisable shapes. Spider naevi represent an issue within skin arterioles (small arteries which supply the skin with blood). Arterioles open and close to control the loss of heat from the body’s surface. But sometimes they can get stuck open – and a spider-like pattern will appear.

  • Crush the body under a fingertip and the whole thing disappears, as your touch temporarily stops the blood flow.
  • Treat the underlying cause, and the spiders often vanish with time – though they may persist or reappear later.

Black velvet

  • This “black velvet” skin appearance is more commonly seen in darker skins.
  • Usually, the condition is associated with disorders of the metabolism – namely type 2 diabetes and polycystic ovary syndrome.

Butterfly rashes

  • Cardiac valves have the important role of correctly directing the journey of blood through the heart and preventing backflow.
  • The body’s natural response is to preserve core blood volume, shutting off flow towards the skin.
  • The net effect can produce a purple-red rash, high across the cheeks and the bridge of the nose, like the outstretched wings of a butterfly.


Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

City of Hope Predicts 8 Important Cancer Trends in 2024

Retrieved on: 
Wednesday, January 17, 2024

City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.

Key Points: 
  • City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.
  • “City of Hope will soon launch a comprehensive research study validating a blood test developed by researchers at City of Hope and TGen to detect cancers early.
  • Early detection is the key to curing cancer for many,” said Annette Walker, president of City of Hope Orange County.
  • “This is a primary reason City of Hope expanded its National Cancer Institute-designated expertise to Chicago, Phoenix and Atlanta.

Debbie's Dream Foundation: Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2023

Retrieved on: 
Wednesday, January 3, 2024

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners. The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors. This year, DDF worked closely with sponsors such as Amgen, Arcus, Astellas, Bristol Myers Squibb (BMS), Daiichi Sankyo (DSI), Genentech, Lilly Oncology, Merck, Taiho Oncology, and Zymeworks, whose dedication has been instrumental in advancing various programs, ensuring DDF's continued service to patients, their families, and caregivers.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners.
  • The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors.
  • At the top of the year, DDF hosted its Inaugural Patient Advocate Retreat during its 11th Annual Stomach Cancer Capitol Hill Advocacy Day in Washington, D.C.
  • For the 2023 Symposia series, DDF collaborated with Moffitt Cancer Center in Tampa, Florida, to host a Stomach Cancer Educational Symposium.

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Retrieved on: 
Tuesday, November 14, 2023

Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
  • PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic that can identify gastric or GEJ adenocarcinoma patients suitable for treatment with KEYTRUDA in combination with chemotherapy and trastuzumab plus fluoropyrimidine.
  • This marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval.
  • PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck (known as MSD outside the United States and Canada) as a companion diagnostic for KEYTRUDA.

Debbie's Dream Foundation Helps Light Up More Than 175 Monuments Worldwide with Gastric Cancer Awareness Day Campaign

Retrieved on: 
Friday, November 24, 2023

FORT LAUDERDALE, Fla., Nov. 24, 2023 /PRNewswire/ -- As Gastric Cancer Awareness Month unfolds, Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly announces a monumental achievement in partnership with My Gut Feeling Stomach Cancer Foundation of Canada (MGF). In just the first year of DDF joining the 'Power of Periwinkle,' an annual campaign hosted by MFG, more than 175 global monuments are confirmed to be illuminated in periwinkle honor of Gastric Cancer Awareness Day on November 30, 2023. Notable locations in the U.S. include the One World Trade Center and the 4 Times Square in New York, the Guitar Hotel at Seminole Hardrock in Florida, and Caesar's Superdome in New Orleans. International sites include the world-famous Niagra Falls, the Leaning Tower of Pisa, and the Kyoto Tower.

Key Points: 
  • FORT LAUDERDALE, Fla., Nov. 24, 2023 /PRNewswire/ -- As Gastric Cancer Awareness Month unfolds, Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly announces a monumental achievement in partnership with My Gut Feeling Stomach Cancer Foundation of Canada (MGF).
  • Andrea Eidelman, CEO of Debbie's Dream Foundation, expresses her excitement: "We are thrilled to celebrate this incredible milestone, raising awareness worldwide about Gastric Cancer Awareness Day and Month.
  • This success sets the stage for the potential expansion of this collaborative effort as we strive to shine an even brighter light on stomach cancer awareness."
  • For more information about Debbie's Dream Foundation: Curing Stomach Cancer, please visit www.DebbiesDream.org .

Debbie's Dream Foundation Shines a Spotlight on Stomach Cancer During Gastric Cancer Awareness Month

Retrieved on: 
Wednesday, November 1, 2023

FORT LAUDERDALE, Fla., Nov. 1, 2023 /PRNewswire/ -- In observance of Gastric Cancer Awareness Month this November, Debbie's Dream Foundation: Curing Stomach Cancer (DDF) has launched an array of impactful initiatives to boost awareness and support for those impacted by stomach cancer, a disease often diagnosed at an advanced stage.

Key Points: 
  • FORT LAUDERDALE, Fla., Nov. 1, 2023 /PRNewswire/ -- In observance of Gastric Cancer Awareness Month this November, Debbie's Dream Foundation: Curing Stomach Cancer (DDF) has launched an array of impactful initiatives to boost awareness and support for those impacted by stomach cancer, a disease often diagnosed at an advanced stage.
  • DDF's major undertaking this month is its first-time partnership with My Gut Feeling: Stomach Cancer Foundation of Canada in their annual "The Power of Periwinkle" monument lighting campaign.
  • DDF, alongside international allies Vivere Senza Stomaco (Italy) and Kibounokai (Japan), is illuminating over 30 locations across the United States in periwinkle blue, commemorating Stomach Cancer Awareness Day on November 30, 2023.
  • DDF's CEO, Andrea Eidelman, stresses the significance of these efforts, saying, "Stomach cancer often goes unnoticed until it reaches an advanced stage.

Stupid Strong Charitable Foundation Pledges $450,000 Grant to Advance Gastric Cancer Family Study

Retrieved on: 
Wednesday, November 1, 2023

This grant will propel the "Cancer Patients' Family Matters" study led by Dr. Jaffer Ajani, aimed at unraveling the mysteries behind the hereditary nature of gastric cancer and developing strategies for early detection and prevention.

Key Points: 
  • This grant will propel the "Cancer Patients' Family Matters" study led by Dr. Jaffer Ajani, aimed at unraveling the mysteries behind the hereditary nature of gastric cancer and developing strategies for early detection and prevention.
  • The research, supported by Stupid Strong, will focus on enrolling gastric cancer patients and their family members, totaling 500 patients and 5,000 individuals overall.
  • This generous grant from the Stupid Strong Charitable Foundation will enable Dr. Ajani to hire staff, identify study participants, administer detailed lifestyle questionnaires, and collect and process blood samples.
  • For more information about the Stupid Strong Charitable Foundation, please visit www.stupidstrong.org .

AI Medical Service Inc. Signs Joint Research Agreement with Leading Vietnamese Medical Institution

Retrieved on: 
Thursday, October 12, 2023

AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Institute of Gastroenterology and Hepatology (hereinafter IGH) and will begin research activities on October 27, 2023.

Key Points: 
  • AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Institute of Gastroenterology and Hepatology (hereinafter IGH) and will begin research activities on October 27, 2023.
  • AIM is the first Japanese company to sign a joint research agreement with IGH in the field of endoscopic AI, and IGH is the first Vietnamese institute that AIM has collaborated with thus far1.
  • Its collaboration with IGH will facilitate joint research designed to test the application of Japanese endoscopic AI in Vietnam.
  • Comment from CEO of AIM Tomohiro Tada, M.D., Ph.D.
    "I am very pleased that we have established a joint research agreement with IGH, one of the leading research institutes in Vietnam.

Debbie's Dream Foundation: Curing Stomach Cancer Launches the 2023 Youth Art Contest: Igniting Young Minds Against Stomach Cancer

Retrieved on: 
Friday, September 29, 2023

FORT LAUDERDALE, Fla., Sept. 29, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is thrilled to announce the return of the 2023 Youth Art Contest. This initiative encourages artists aged 18 and under to unleash their creativity and raise awareness about stomach cancer, a cause dear to late DDF Founder Debbie Zelman.

Key Points: 
  • DDF encourages young artists to spark their creativity while joining the fight against stomach cancer.
  • FORT LAUDERDALE, Fla., Sept. 29, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is thrilled to announce the return of the 2023 Youth Art Contest.
  • This initiative encourages artists aged 18 and under to unleash their creativity and raise awareness about stomach cancer, a cause dear to late DDF Founder Debbie Zelman.
  • The contest opened on September 15, 2023, welcoming young artists and photographers to submit their original works for consideration in the prestigious DDF 2024 Youth Art Calendar.